Dr Jeffery Matous at ASH 2014: Phase I MM-008 study of pomalidomide and dexamethasone in relapsed/refractory myeloma with renal impairment

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses combination approaches and novel monoclonal antibodies in multiple myeloma.

The phase I MM-008 study is assessing the pharmacokinetics and safety of pomalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma and renal impairment.